Trial: 202011112

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

Phase

II

Principal Investigator

Chheda, Milan

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov